Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06613568 · ClinicalTrials.gov registry record · NA

Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants

A NA study of End-Stage Kidney Disease, sponsored by Diality.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
4
Study locations

NCT06613568: Recruiting NA study of End-Stage Kidney Disease, sponsored by Diality.

NCT06613568 is a NA study of End-Stage Kidney Disease that is actively recruiting participants, run by Diality. The registered enrollment target is 50 participants, below the 463-participant average among 20 other End-Stage Kidney Disease trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06613568, a NA study of End-Stage Kidney Disease, is actively recruiting participants, sponsored by Diality.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of the Moda-flx Hemodialysis System™ when used Under Professional Care Settings by trained individuals and At Home by trained Participants and Care Partners

Primary Outcome

Standardized weekly (stdKt/V) values as measured once every week during the Professional Care and At Home treatment settings

Conditions Studied

Interventions

  • DEVICE Moda-flx Hemodialysis System™

Study Locations (4)

California

  • North America Research Institute - San Dimas

Tennessee

  • Nephrology Associates of Knoxville - Knoxville

Texas

  • aQua Research Institute, LLC - Houston

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-10-06
Est. Completion 2027-09
Phase NA
Diality

2 total trials

What NCT06613568 shows while recruiting

NCT06613568 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 463-participant average among 20 other End-Stage Kidney Disease trials with a reported enrollment target (89% lower).

The record links to 1 condition, with End-Stage Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Moda-flx Hemodialysis System™ is the first listed.

NCT06613568 reports a single indexed study location in California, Tennessee, Texas.

Frequently Asked Questions

What is clinical trial NCT06613568 about?

NCT06613568 is a clinical study titled "Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants". The purpose of this study is to evaluate the safety and efficacy of the Moda-flx Hemodialysis System™ when used Under Professional Care Settings by trained individuals and At Home by trained Participants and Care Partners

What is the current status of trial NCT06613568?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-10-06. Estimated completion is 2027-09.

What conditions does trial NCT06613568 study?

This clinical trial studies the following conditions: End-Stage Kidney Disease.

What interventions are being tested in trial NCT06613568?

The interventions under investigation include: Moda-flx Hemodialysis System™ (DEVICE).

Who is sponsoring clinical trial NCT06613568?

This trial is sponsored by Diality, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06613568 being conducted?

This trial has 4 study locations across California, Tennessee, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End-Stage Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06613568's enrollment target sits among peer trials

50 14th of 20 higher than 7 of 20 other End-Stage Kidney Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other End-Stage Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06613568, the US trial registry maintained by the National Library of Medicine. NCT06613568 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.